These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 32811654)

  • 1. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
    Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
    Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
    Wang HY; Dou KF; Wang Y; Yin D; Xu B; Gao RL
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):663-675. PubMed ID: 32601780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk "TWILIGHT-like" Patients With Diabetes Mellitus.
    Wang HY; Cai ZX; Yin D; Song WH; Feng L; Gao RL; Yang YJ; Dou KF
    Front Cardiovasc Med; 2020; 7():586491. PubMed ID: 33330647
    [No Abstract]   [Full Text] [Related]  

  • 4. Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
    Wang HY; Cai ZX; Yin D; Yang YJ; Song WH; Dou KF
    Am J Cardiol; 2021 Mar; 142():14-24. PubMed ID: 33285091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome.
    Wang HY; Mo R; Guan CD; Wang Y; Zhao YY; Xie LH; Zhang R; Cai ZX; Xu B; Dou KF
    Catheter Cardiovasc Interv; 2022 Jan; 99(1):98-113. PubMed ID: 33909311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
    J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
    Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T;
    JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction.
    Veron-Esquivel D; Batiz-Armenta F; Cazares-Diazleal AC; Oviedo-Moguel S; Jarvio-Fernandez SM; Arce-Gonzalez JM; Ivey-Miranda JB
    Hellenic J Cardiol; 2019; 60(5):296-302. PubMed ID: 29807194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
    Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
    BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI.
    Giustino G; Chieffo A; Palmerini T; Valgimigli M; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Gilard M; Morice MC; Sawaya F; Sardella G; Genereux P; Redfors B; Leon MB; Bhatt DL; Stone GW; Colombo A
    J Am Coll Cardiol; 2016 Oct; 68(17):1851-1864. PubMed ID: 27595509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
    Piccolo R; Feres F; Abizaid A; Gilard M; Morice MC; Hong MK; Kim HS; Colombo A; Bhatt DL; Palmerini T; Stone GW; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1621-1630. PubMed ID: 28838471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
    Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
    Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI.
    Wang HY; Gao RL; Xu B; Yang YJ; Yin D; Wang Y; Dou KF
    Platelets; 2021 May; 32(4):533-541. PubMed ID: 32498587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.
    Ishida M; Takahashi F; Goto I; Niiyama M; Saitoh H; Sakamoto T; Maegawa Y; Osaki T; Nishiyama O; Endo H; Sakamoto R; Kojima T; Koeda Y; Kimura T; Itoh T; Morino Y;
    Cardiovasc Interv Ther; 2020 Oct; 35(4):398-404. PubMed ID: 32776221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
    Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.